Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia
Context A portion of patients with chronic myeloid leukaemia (CML) develop resistance to the Bcr-Abl tyrosine kinase inhibitors (TKIs), limiting the clinical applications. Previous results have demonstrated the synergistic effects between cryptotanshinone (CPT) and imatinib on apoptosis of CML cells...
Main Authors: | Rubin Cheng, Yilan Huang, Yun Fang, Qirui Wang, Meixiu Yan, Yuqing Ge |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Pharmaceutical Biology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/13880209.2021.1944224 |
Similar Items
-
Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01) -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
by: Gianfranco Catalano, et al.
Published: (2020-10-01) -
The pro-metastasis tyrosine phosphatase, PRL-3 (<it>PTP4A3</it>), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia
by: Zhou Jianbiao, et al.
Published: (2012-09-01) -
Zur Behandlung der chronischen myeloischen Leukämie mit dem selektiven bcr-abl Tyrosinkinaseinhibitor Imatinib
by: Na, Il-Kang
Published: (2005) -
Tyrosine kinase inhibitors in hematological malignancies
by: Kamila Kosior, et al.
Published: (2011-12-01)